,
Lanzetta, Paolo https://orcid.org/0000-0003-3746-141X
Sarao, Valentina
Scanlon, Peter H.
Barratt, Jane
Porta, Massimo
Bandello, Francesco
Loewenstein, Anat
Article History
Received: 17 December 2019
Accepted: 14 February 2020
First Online: 28 March 2020
Change Date: 18 May 2020
Change Type: Correction
Change Details: Authors would like to correct few errors in their publication which are listed below.
Compliance with ethical standards
:
: Paolo Lanzetta has received honoraria for speaking at symposia; financial support for attending symposia; financial support for educational programs; and consultation fees from Bayer, Centervue and Novartis. Valentina Sarao has no potential conflicts of interest to declare. Peter H. Scanlon has received advisory board or speaker fees from Allergan, Bayer, Boehringer Ingelheim, Pfizer, Roche and Novartis; and support for attending meetings from Bayer. His institution has received educational research or audit grants from Allergan, Bayer, Boehringer Ingelheim, Novartis and Pfizer. Jane Barratt has no potential conflicts of interest to declare. Massimo Porta has received advisory board and speaker fees from Allergan, Novartis and SIFI. Francesco Bandello has received consultancy fees from Allergan, Bayer, Boehringer Ingelheim, Fidia, Hoffmann La Roche, Novartis, NTC Pharma, SIFI, Thrombogenics and Zeiss. Anat Loewenstein has received consultancy fees or advisory board fees from Allergan, Alcon, Bayer, Beyeonics Surgical, Neutech, Notal Vision, Novartis, Roche and Syneos Health. Her institution has received research grants/support from Allergan, Bayer, Sensor and Novartis.
: This article does not contain research involving human or animal subjects.
: For an expert opinion publication like this, no consent is required.